Tuesday, 19 August 2025 at 11.00 - 12.00h CEST
In connection with the publication of Coloplast’s interim financial results for 9M 2024/25, to be released same day in the morning around 07.30h CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.
The webcast of the conference call will be available during and after the event.
Related Questions
What is the outlook for full‑year 2024/25 earnings and guidance – any revisions to revenue, EBITDA, or EPS forecasts?
How does the current valuation (P/E, EV/EBITDA) compare to key competitors in the medical device sector after this release?
How did currency fluctuations (euro, US $) affect the reported results, and what hedging strategies are in place?
What is the expected impact of the 9M results on the stock’s technical indicators (e.g., support/resistance levels) in the short‑term?
What were the revenue growth rates and margins for the 9 months, and how do they compare year‑over‑year and to the prior quarter?
What is the current free cash flow generation and its impact on planned share buy‑backs or capital allocation?
Are there any upcoming catalysts or events (e.g., regulatory approvals, M&A activity, conferences) that could influence the stock price in the near term?
How did the 9M 2024/25 earnings compare to analyst expectations and consensus forecasts?
Are there any changes to the dividend policy or payout ratio following the interim results?
What are the expectations for the upcoming FY 2025/26 guidance, especially regarding the product pipeline and upcoming product launches?
Did management comment on any macro‑economic or regulatory risks that could affect future performance?
Which Business Units (e.g., Colostomy, Urology, Wound Care) drove the performance, and were there any notable segment trends?